Human PD-1 Monoclonal Antibody
Produktgrößen
1 mg
£355,00
YR0096-1MG
5 mg
£885,00
YR0096-5MG
20 mg
£2835,00
YR0096-20MG
Über dieses Produkt
- SKU:
- YR0096
- Zusätzliche Namen:
- CD279|hPD-1|hPD-l|hSLE1|PD1|PDCD1|SLEB2
- Anwendung:
- Block/Inhibit/Neutralise, Cell-based/Functional Assay, ELISA
- Klonalität:
- Monoclonal
- Weitere Details:
- Cemiplimab Biosimilar uses the same protein sequences as the therapeutic antibody cemiplimab.PD-L1 and PD-L2 (B2-DC or CD273, programmed cell death ligand 2) are the two ligands for the receptor PD-1 (CD279, programmed cell death protein 1).Cemiplimab (anti-PD-1) is an intravenous human monoclonal antibody directed against programmed cell death-1 receptor (PD-1) and blocks its interaction with programmed death ligands 1 (PD-L1) and 2 (PD-L2). Cemiplimab blocks T-cell inactivation and enhances the immune system's anti-tumor response.Binding of the programmed death receptor (PD) ligands PD-L1 and PD-L2, to the PD-1 receptor inhibits T-cell proliferation and cytokine production. The upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway may contribute to the inhibition of active T-cell immune surveillance of tumors. Cemiplimab is a recombinant human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2 ligands, causing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In mouse tumor models, blocking PD-1 activity resulted in decreased rates of tumor growth.
- Formulierung:
- Purified from cell culture supernatant in an animal-free facility
- Immunogen:
- Human PD-1
- Isotyp:
- IgG4, kappa
- Molekulargewicht:
- 150 kDa
- Reinheit:
- >95%
- Versandbedingungen:
- Blue Ice
- Lagerbedingungen:
- 2-8[o]C Avoid freeze/thaw cycles., -70[o]C Avoid freeze/thaw cycles.
- Hersteller:
- ABclonal Technology
- Typ:
- Antibody: Biosimilar Antibody
- Datenblatt des Herstellers:YR0096